The CGM Problem is Solvable.
We're Solving It.

Continuous Glucose Monitoring remains a luxury for the few. With 101M Indians living with diabetes and average costs exceeding ₹4,500 per sensor, the math of health is broken.

The Opportunity

Market Failure as Infrastructure Need.

101M

People in India living with diabetes, representing the world's most significant concentrated health challenge.

<2%

Market penetration for CGM technology due to prohibitive costs and import dependency.

₹4,500

Average monthly recurring cost for current solutions. Far beyond the median Indian household capability.

We are building toward ₹999 per sensor.
A 75% reduction in cost with 100% of the clinical rigor.

Our Thesis

Why Now?

The convergence of three technological and geopolitical shifts makes the EZSense mission inevitable.

01

Microneedle Maturity

Advancements in MEMS (Micro-Electro-Mechanical Systems) allow for painless, high-fidelity interstitial fluid sensing that was previously impossible to mass-produce at scale.

02

Commoditized BLE Chipsets

The evolution of ultra-low-power Bluetooth System-on-Chips (SoCs) has dropped radio costs by 60% in the last 24 months, enabling true single-use disposability.

03

Manufacturing Stack

The emergence of high-precision medical electronic manufacturing in India allows us to bypass global supply chain premiums and design for the domestic price point.

The Roadmap

Three Phases to Accessibility.

2025: Precision

Core Sensor Alpha

Validation of electrochemical stability and micro-scale electrode manufacturing in a research environment.

2026: Scale

Mass-Yield Prototypes

Transitioning from lab bench to 10k unit pilot runs. Clinical trials and regulatory submission.

2027-28: Impact

National Rollout

Achieving the ₹999 price point through ecosystem partnerships and public health integration.

For Strategic Investors

We are seeking patient capital from partners who understand that the greatest impact in MedTech comes from widening the funnel of accessibility.

Review Thesis

For Research Partners

We are open to academic collaborations regarding enzyme longevity, biocompatible coatings, and signal processing.

Access Portal

"What UPI did for finance and Jio did for data, EZSense will do for metabolic health."

The EZSense Vision 2030

Stealth Notice

EZSense is currently in deep-research mode. We are intentionally avoiding public publicity to focus on engineering benchmarks. Information shared during interest calls is subject to non-disclosure.

Start a Conversation.

Inquiries are reviewed by our lead research team.